UJALA FAWAD: Open Payments
NPI 1063662112 · NORWOOD, MA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,918 in 109 payments from 17 companies in 2025. Trend: 2023 $578 · 2024 $1,680 · 2025 $1,918
Food & beverage: $1,763Education: $155
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 28 | $376 |
| ABBVIE INC. | 14 | $214 |
| Axsome Therapeutics, Inc. | 8 | $168 |
| Lundbeck LLC | 8 | $162 |
| Otsuka America Pharmaceutical, Inc. | 7 | $162 |
| Corium, LLC | 9 | $149 |
| Supernus Pharmaceuticals, Inc. | 8 | $137 |
| E.R. Squibb & Sons, L.L.C. | 5 | $105 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $90 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 4 | $83 |
Products named: FANAPT, REXULTI, VRAYLAR, Auvelity, Azstarys, Qelbree, CAPLYTA, COBENFY.
Industry payments across MA — which companies pay providers there.
